Back to mobile site

JPMorgan Starts MBX Biosciences Inc (MBX) at Overweight

October 8, 2024 3:45 AM EDT Send to a Friend
JPMorgan analyst Jessica Fye initiates coverage on MBX Biosciences Inc (NASDAQ: MBX) with a Overweight rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login